Keytruda biosimilars are coming — but they face an uphill battle
BioPharma DiveTopic alignment 92
A patent cliff is fast approaching for Merck’s flagship blockbuster, but the deck might be stacked against its biosimilars gaining widespread traction.
Filed under
- Biosimilarsmatch 92
Teva and Samsung Bioepis Enter Into Licensing Agreement to Commercialize Etanercept and Infliximab Biosimilars in the U.S.
Big Molecule WatchTopic alignment 85
FDA Approves Xbrane’s LUCAMZI™, a Biosimilar to LUCENTIS®
Big Molecule WatchTopic alignment 90
How the Biosimilars Access and Affordability Act Redefines IRA Delays
The Center for BiosimilarsTopic alignment 92
Teva Licenses U.S. Rights to Infliximab, Etanercept Biosimilars
PharmExec (Pharmaceutical Executive)Topic alignment 90